2:55 PM
 | 
Feb 22, 2019
 |  BioCentury  |  Finance

MPM keeps building

How MPM is deploying three investment vehicles to support company building

MPM Capital’s new $400 million BioVentures 2018 fund will complement the firm’s cancer-focused initiatives and enable it to continue its company building strategy.

BioVentures 2018 closed on Feb. 21 and follows in the footsteps of BioVentures 2014 fund, which closed at $400 million in 2015 with a focus on building startups (see “New (Bio)Ventures at MPM”).

“We’re very squarely situated on the early stage end of the spectrum,” MPM’s Luke Evnin told BioCentury. “It’s really a linear successor to what we’ve been doing.”

“We’re very squarely situated on the early stage end of the spectrum.”

Luke Evnin, MPM...

Read the full 474 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >